CC‐99282 plus R‐CHOP in patients (pts) with previously untreated aggressive B‐cell lymphoma (a‐BCL): early safety and efficacy results from a phase 1b study.

Autor:	Munoz, J., Hoffmann, M., Westin, J., Vassilakopoulos, T. P., García‐Sancho, A. M., Rueda‐Domínguez, A., Jurczak, W., Kwiatek, M., Bouzani, M., Gkasiamis, A., Patel, A., Boucaud, F., Li, J., Nowakowski, G. S.
Předmět:	ANTINEOPLASTIC combined chemotherapy protocols LYMPHOMAS NON-Hodgkin's lymphoma
Zdroj:	Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p584-586, 3p
Abstrakt:	CC-99282 plus R-CHOP in patients (pts) with previously untreated aggressive B-cell lymphoma (a-BCL): early safety and efficacy results from a phase 1b study CC-220-DLBCL-001 (NCT04884035) is an open-label, multicenter, dose-escalation and expansion trial to assess safety and preliminary efficacy of CC-99282 or CC-220 plus R-CHOP for untreated a-BCL. B Introduction: b Up to 30-40% of pts with diffuse large BCL relapse/become refractory after first-line chemo-immunotherapy with R-CHOP. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text